All In Biotech

Drug Trial Radar · NCT07102901

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

A Multicenter, Open-Label Phase II Clinical Study Evaluating the Safety, Tolerability and Efficacy of SHR2554 Tablets in Combination With Other Antitumor Therapies in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

351

Planned (sponsor's estimate)

Start

Sep 5, 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Aug 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Conditions

  • Advanced Gastric Cancer
  • Metastatic Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma

Interventions

  • SHR2554 TabletsDrug

    Oral SHR2554 tablets.

  • SHR-A1811 InjectionDrug

    SHR-A1811 for injection.

  • SHR-A1904 InjectionDrug

    SHR-A1904 for injection.

  • SHR-1701 InjectionDrug

    SHR-1701 injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs).Time frame: Up to approximately 2 years.
  2. Incidence and severity of serious adverse events (SAEs).Time frame: Up to approximately 2 years.
  3. Incidence of Dose Limited Toxicity (DLT).Time frame: Up to Day 21.
  4. Objective response rate (ORR) by the investigator assessment.Time frame: Up to approximately 1 year.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.